Nastro Marcela, Montoto Piazza Luciana, Saposnik Elsa, García Susana, Barberis Claudia, Vay Carlos, Rodríguez Carlos H, Famiglietti Angela
Laboratorio de Bacteriologí Clínica, Departmento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.
Rev Argent Microbiol. 2012 Jan-Mar;44(1):30-5. doi: 10.1590/S0325-75412012000100007.
The aims of this study were to evaluate the in vitro activity of extended-spectrum cephalosporins (ESC) in non-inducible AmpC enterobacteria throµgh phenotypic and genotypic characterization of the mechanisms of resistance (ESBL, plasmid-mediated AmpC and KPC) and to evaluate the interpretation criteria proposed by the existing recommendations and the new breakpoints established by the CLSI and the EUCAST. Susceptibility tests and PCR multiplex for b/aSHV and b/aCTX-M and amplification using specific primers was performed. One hundred sixty nine resistant isolates: K/ebsie//a pneumoniae (95), Escherichia co/i (55), and Proteus mirabi/is (19) were recovered. ESC resistance was 56.2 %, 32.6%, and 11.2 %, respectively. ESBL was detected in 152 (90 %) isolates, plasmid-mediated AmpC in 12 (7 %) and KPC in 5 (3 %). The CLSI 2009 recommendations and the breakpoints sµggested by the CLSI 2010 and the EUCAST for ceftriaxone were efficacious to detect ESBL, whereas the different breakpoints for ceftazidime presented discrepancies. The CLSI 2010 breakpoints only detected 55 % of the ESBL-producing isolates due to the endemic presence of CTX-M ESBLs in our country. Regarding the plasmid-mediated AmpC producers, the recommendations of the CLSI 2010 and the EUCAST 2010 proved to be more efficient than the old ones.
本研究的目的是通过对耐药机制(超广谱β-内酰胺酶、质粒介导的AmpC和KPC)进行表型和基因型特征分析,评估超广谱头孢菌素(ESC)对非诱导型AmpC肠杆菌的体外活性,并评估现有指南提出的解释标准以及美国临床和实验室标准协会(CLSI)与欧洲药敏试验委员会(EUCAST)制定的新断点。进行了针对b/aSHV和b/aCTX-M的药敏试验及多重PCR,并使用特异性引物进行扩增。共分离出169株耐药菌株:肺炎克雷伯菌(95株)、大肠埃希菌(55株)和奇异变形杆菌(19株)。ESC耐药率分别为56.2%、32.6%和11.2%。在152株(90%)菌株中检测到超广谱β-内酰胺酶,12株(7%)为质粒介导的AmpC,5株(3%)为KPC。CLSI 2009指南以及CLSI 2010和EUCAST提出的头孢曲松断点对于检测超广谱β-内酰胺酶是有效的,而头孢他啶的不同断点存在差异。由于我国CTX-M超广谱β-内酰胺酶的地方性流行,CLSI 2010断点仅检测到55%的产超广谱β-内酰胺酶菌株。对于质粒介导的AmpC产生菌,CLSI 2010和EUCAST 2010的指南比旧指南更有效。